Ascendis Pharma Plans $120 Million Share Repurchase Program In 2026

Like
Comment
Favorite

Ascendis Pharma Plans $120 Million Share Repurchase Program In 2026

Reuters01-10

Jan 9 (Reuters) - Ascendis Pharma A/S ::
*ASCENDIS PHARMA PROVIDES BUSINESS AND STRATEGIC ROADMAP UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
*PLANS $120 MILLION SHARE REPURCHASE PROGRAM IN 2026
*EXPECT OPERATING CASH FLOW OF €500 MILLION IN 2026
*TOTAL FULL-YEAR 2025 PRELIM REVENUE OF €720 MILLION
*FULL-YEAR 2025 GROSS MARGIN EXPECTED TO BE 87%

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 09-JAN-202623:01:32.14 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2602022503?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-10 07:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602022503","market":"nz","top_or_hot":-1,"title":"Ascendis Pharma Plans $120 Million Share Repurchase Program In 2026","media":"Reuters","content":"<html><body>Jan 9 (Reuters) - <a href=\"https://laohu8.com/S/ASND\">Ascendis Pharma A/S</a> <a71.f>::<br/>*ASCENDIS PHARMA PROVIDES BUSINESS AND STRATEGIC ROADMAP UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE<br/>*PLANS $120 MILLION SHARE REPURCHASE PROGRAM IN 2026<br/>*EXPECT OPERATING CASH FLOW OF €500 MILLION IN 2026<br/>*TOTAL FULL-YEAR 2025 PRELIM REVENUE OF €720 MILLION<br/>*FULL-YEAR 2025 GROSS MARGIN EXPECTED TO BE 87%<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 09-JAN-202623:01:32.14 GMT</a71.f></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascendis Pharma Plans $120 Million Share Repurchase Program In 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscendis Pharma Plans $120 Million Share Repurchase Program In 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-10 07:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Jan 9 (Reuters) - <a href=\"https://laohu8.com/S/ASND\">Ascendis Pharma A/S</a> <a71.f>::<br/>*ASCENDIS PHARMA PROVIDES BUSINESS AND STRATEGIC ROADMAP UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE<br/>*PLANS $120 MILLION SHARE REPURCHASE PROGRAM IN 2026<br/>*EXPECT OPERATING CASH FLOW OF €500 MILLION IN 2026<br/>*TOTAL FULL-YEAR 2025 PRELIM REVENUE OF €720 MILLION<br/>*FULL-YEAR 2025 GROSS MARGIN EXPECTED TO BE 87%<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 09-JAN-202623:01:32.14 GMT</a71.f></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4135","symbol_name":"资产管理与托管银行","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nRSD9z57BR:1","article_id":"2602022503","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602022503","pubTimestamp":1768000995,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jan 9 (Reuters) - Ascendis Pharma A/S ::*ASCENDIS PHARMA PROVIDES BUSINESS AND STRATEGIC ROADMAP UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE*PLANS $120 MILLION SHARE REPURCHASE PROGRAM IN ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4135":"资产管理与托管银行","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","BK4585":"ETF&股票定投概念","ASND":"Ascendis Pharma A/S","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","BK":"纽约梅隆银行","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4559":"巴菲特持仓","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC"},"translate_title":"Ascendis Pharma计划在2026年实施1.2亿美元的股票回购计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BK":0.9,"ASND":0.9},"content_text":"Jan 9 (Reuters) - Ascendis Pharma A/S ::*ASCENDIS PHARMA PROVIDES BUSINESS AND STRATEGIC ROADMAP UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE*PLANS $120 MILLION SHARE REPURCHASE PROGRAM IN 2026*EXPECT OPERATING CASH FLOW OF €500 MILLION IN 2026*TOTAL FULL-YEAR 2025 PRELIM REVENUE OF €720 MILLION*FULL-YEAR 2025 GROSS MARGIN EXPECTED TO BE 87%  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 09-JAN-202623:01:32.14 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}